Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty

(BUSINESS WIRE) -- Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing desire for effortless, authentic results that restore facial balance and improve skin quality, the campaign highlights Restylane’s unique ability to deliver personalized results that move naturally with expressions to help people look and feel good.^1,6,12-18

The launch was unveiled at the IMCAS World Congress 2026 in Paris, where Galderma also presented new clinical data reinforcing Restylane’s efficacy across key facial areas such as the chin, jawline, temples, as well as the décolletage, underscoring its unique position as the only HA portfolio offering a variety of formulations for tailored outcomes.^1,8-11

As HA treatments remain the go-to for modern beauty, Restylane helps people wake up ready to go

‘Wake Up To Restylane’ captures a growing desire to look subtly refreshed – like you slept well – without the effort, especially towards beauty-conscious consumers, some of whom might be new to injectables, and want results that look authentic and harmonious, while aligning with their lifestyles. Restylane delivers what skincare and makeup alone can’t: structure, definition, balance, and a lasting glow, thanks to its unique HA that works in sync with your skin.^1,6,12-18

Insights from Galderma’s research of over 4,300 consumers and healthcare professionals (HCPs) across four countries (Brazil, China, Germany and the United States) highlight the relevance of this campaign.¹² HA treatments remain an important aesthetic treatment option, with about a third of consumers ranking HA as their top injectable choice ahead of neuromodulators.¹² HA treatments remain among the most planned procedures globally, which signals the durable relevance and trust in the category.¹²

HAs are often chosen for deeply personal reasons: people describe HA treatments as an act of self‑care and self‑love, a little indulgence in a stressful life that helps them feel comfortable in their own skin.¹² Many are choosing HA specifically to improve skin quality, seeking healthy, glowing, hydrated skin that looks refreshed.¹² Patients and practitioners align on natural‑looking results, delivered safely and with reliable outcomes.¹² This aligns perfectly with Restylane’s promise: authentic beauty that’s ready when you are, supported by three decades of safety data.^1-3

Restylane: Backed by science and designed differently, with proven versatility across facial areas and skin concerns

The versatile portfolio of Restylane HA treatments is designed to meet diverse patient needs across key areas of the face and décolletage, from soft, flexible formulations that smooth facial lines and wrinkles for a more youthful look, to firmer gels that provide contouring and structural support.^2,5-11,13-21

Ongoing clinical evidence continues to reinforce Restylane’s ability to deliver natural-looking, long-lasting results across multiple indications.^8-11 New clinical data presented at IMCAS demonstrated the efficacy of Restylane Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, and Restylane Volyme™ in correcting hollowing of the temples, while Restylane Skinboosters™ improved skin quality and smoothed wrinkles in the décolletage – an area often affected by sleep lines.^8-11

With over 30 years of innovation and more than 77 million treatments administered worldwide, Restylane remains highly relevant in addressing some of today’s most significant aesthetic trends and needs, from facial changes following medication-driven weight loss to growing concerns related to menopause and skin health.^1,22-24 Galderma’s continued innovation underscores its commitment to helping people feel good in their skin at every life stage.

About the Restylane portfolio

Restylane hyaluronic acid (HA) treatments are designed differently to go beyond volumizing for natural-looking results.^1,25-27 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.^12,28-30 Powered by NASHA^®, NASHA HD™, OBT™ and SB-NASHA™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.^4-7 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.^1-3

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1. Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.

2. Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.

3. Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.13205.

4. Galderma Data on file. MA-56724. X-strain and G’ including Shaype.

5. Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145.

6. Öhrlund Å et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. J Drugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.

7. Belmontesi M et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus. J Drugs Dermatol. 2018;17(1):83–88.

8. Nikolis A, et al. A new NASHA-HD, high G’ hyaluronic acid (HA) injectable evaluated for chin treatment in combination with lower face and mid-face HA filler treatment. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

9. Rivers J, et al. Effectiveness and safety of Restylane^® Lyft™ Lidocaine for jaw-line definition: A 12-month randomized controlled study. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

10. Moradi A, et al. Effectiveness and safety of a hyaluronic acid skin quality injectable for the correction of wrinkles in the décolletage area. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

11. Nestor, M. Safety and effectiveness of an OBT™ hyaluronic acid filler for temple hollowing treatment: a randomized, controlled, clinical investigation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

12. Galderma. Data on file. Global report: Aesthetics treatments and hyaluronic acid injectables. Consumers & HCPs. 2025.

13. Restylane^® Shaype™. IFU. August 2023. Available online. Accessed January 2026.

14. Restylane^® Lyft™. IFU. August 2023. Available online. Accessed January 2026.

15. Restylane^®. IFU. August 2023. Available online. Accessed January 2026.

16. Restylane^® Eyelight™. IFU. August 2023. Available online. Accessed January 2026.

17. Lee BM, et al. Rejuvenating Effects of Facial Hydrofilling using Restylane Vital. Arch Plast Surg. 2015;42(3):282–287. doi: 10.5999/aps.2015.42.3.282.

18. Distante F, et al. Stabilized hyaluronic acid of non-animal origin for rejuvenating the skin of the upper arm. Dermatol Surg. 2009;35(S)1:389-394. doi: 10.1111/j.1524-4725.2008.01051.x.

19. Hilton S, et al. Randomized, Evaluator-Blinded Study Comparing Safety and Effect of Two Hyaluronic Acid Gels for Lips Enhancement. Dermatol Surg. 2018;44(2):261–269. doi: 10.1097/DSS.0000000000001282.

20. Restylane^® Skinboosters Vital Lidocaine™. IFU. August 2022. Available online. Accessed January 2026.

21. Restylane^® Skinboosters Vital Light Lidocaine™. IFU. August 2021. Available online. Accessed January 2026.

22. Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.

23. Fabi SG, et al. The potential role of biostimulators/dermal fillers to address menopause-related skin conditions. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

24. Lorenc ZP, et al. Synergistic Efficacy and Safety of Poly-L-Lactic Acid Biostimulator and Hyaluronic Acid Filler for Facial Fullness post Weight Loss due to Glucagon-like Peptide-1 Receptor Agonist Medication. Presented at the ASDS 2025 Annual Meeting; November 13-16; Chicago, United States.

25. Restylane. U.S. Instructions for use. Available online. Accessed January 2026.

26. Nikolis A, Enright KM, Lazarova D, et al. The role of clinical examination in midface volume correction using hyaluronic acid fillers: should patients be stratified by skin thickness? Aesthet Surg J Open Forum. 2020;2(1):1–12. doi: 10.1093/asjof/ojaa005.

27. Talarico S, et al. High patient satisfaction of a HA filler producing enduring full-facial volume restoration: an 18- month open multicenter study. Dermatol Surg. 2015;41:1361–1369. doi: 10.1097/DSS.0000000000000549.

28. Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.

29. Galderma. Data on file. MA-58650. Degree of modification of HA fillers.

30. Seo K. Facial volumization with fillers. Springer. 2021;29–83. doi: 10.1007/978-981-33-6212-3_2.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260128829353/en/